

Cardiovascular and Renal Drugs Advisory Committee

December 12, 2007

Sheraton College Park Hotel

Beltsville, Maryland

Draft Meeting Roster

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS

(Voting)

Steven D. Findlay, M.P.H.

Consumer Representative

Health Policy Analyst

Consumers Union

Washington, DC

Frederick J. Kaskel, M.D., Ph.D.

Professor, Department of Pediatrics

Children's Hospital at Montefiore

Albert Einstein College of Medicine of

Yeshiva University

Bronx, NY

Robert A. Harrington, M.D., F.A.C.C.

Professor of Medicine, Division of Cardiology

Department of Medicine

Duke University Medical School

Duke Clinical Research Institute

Durham, NC

Abraham Michael Lincoff, M.D., F.A.C.C.

Professor of Medicine

Department of Cardiovascular Medicine

The Cleveland Clinic Foundation

Cleveland, OH

William R. Hiatt, M.D. (Chair)

Professor of Medicine

University of Colorado

Colorado Prevention Center

Denver, CO

TEMPORARY MEMBERS (Voting)

Barry M. Massie, M.D.

Professor of Medicine

University of California, San Francisco

Chief, Cardiology Section

San Francisco VA Hospital

San Francisco CA

Cardiovascular and Renal Drugs Advisory Committee

December 12, 2007

Sheraton College Park Hotel

Beltsville, Maryland

Draft Meeting Roster

Page 2

INDUSTRY REPRESENTATIVE (Non-Voting)

Jonathan C. Fox, M.D., Ph.D., F.A.C.C.

(Acting) Industry Representative

VP Clinical Therapeutic Area, CVGI

AstraZeneca LP, PO Box 15437

Wilmington, DE

FDA PARTICIPANTS (Non-Voting)

Thomas Marciniak, M.D.

Medical Team Leader

Division of Cardiovascular and Renal Drug Products

FDA/CDER

Norman Stockbridge, M.D.

Director, Division of Cardiovascular and Renal Drug Products

FDA/CDER

Robert Temple, M.D.

Director, Office of Drug Evaluation I (ODEI)

FDA/CDER